| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Calcium dobesilate targets multiple pathways involved in vascular function and inflammation. It has antioxidant activity and helps to reduce oxidative stress and inflammation in the retinas of diabetic mice. It can clear hydroxyl free radicals with an IC50 of 1.1 pM. The compound reduces blood hyper viscosity, restoring normal flow and preventing platelet hyper-aggregation. It can decrease fibrinogen and globulin levels, reduce the high aggregation of red blood cells, activate fibrinolytic enzyme activity, increase the solubility of blood fibrin, thereby reducing blood viscosity. It also reduces the synthesis and release of platelet aggregation factors.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Calcium dobesilate has antioxidant activity, clearing hydroxyl free radicals with an IC50 of 1.1 pM. It has anti-inflammatory and vasoprotective properties. The compound reduces blood hyper viscosity and prevents platelet hyper-aggregation. It can decrease fibrinogen and globulin levels, reduce the high aggregation of red blood cells, activate fibrinolytic enzyme activity, and increase the solubility of blood fibrin. These in vitro activities support its use as a vasoprotective agent for the treatment of chronic venous disease, diabetic retinopathy, and other microvascular disorders.
|
| ln Vivo |
In vivo studies of Calcium dobesilate have demonstrated its efficacy in animal models of diabetic retinopathy and other vascular disorders. The compound reduces oxidative stress and inflammation in the retinas of diabetic mice. It has been used extensively in many countries to study chronic venous disease, diabetic retinopathy, and hemorrhoidal attacks. In vivo protocols typically involve oral administration of Calcium dobesilate at doses determined from clinical studies. Endpoints include assessment of vascular function, retinal pathology, inflammatory markers, and oxidative stress. The compound's efficacy and safety have been established in clinical trials, and it is used as a therapeutic agent in many countries.
|
| Enzyme Assay |
For antioxidant assays, Calcium dobesilate is tested for its ability to scavenge free radicals using various in vitro methods. For hydroxyl radical scavenging, the compound is incubated with a hydroxyl radical-generating system and a probe (e.g., salicylic acid or benzoic acid). The decrease in hydroxyl radical-mediated product formation is measured spectrophotometrically, and IC50 values are calculated. For anti-inflammatory assays, immune cells are cultured and stimulated with LPS in the presence or absence of Calcium dobesilate. Cytokine levels are measured by ELISA. For vascular function assays, endothelial cells are cultured and treated with the compound, and markers of vascular function (e.g., NO production, adhesion molecule expression) are assessed.
|
| Cell Assay |
For cellular studies, endothelial cells or other cell types are cultured in appropriate medium (e.g., DMEM or endothelial cell medium) with 10% FBS and antibiotics. Cells are seeded in 6-well or 96-well plates. Calcium dobesilate is dissolved in water or DMSO and diluted in culture medium to final concentrations (typically 0.1-100 µM). Cells are treated for 24-72 hours. Cell viability is assessed by MTT assay. Oxidative stress markers (ROS, MDA) are measured using fluorescent probes or colorimetric assays. Inflammatory cytokine production is measured by ELISA. For mechanistic studies, cells are lysed and analyzed for signaling proteins (e.g., NF-κB, MAPKs) by Western blot.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of diabetic retinopathy or other vascular disorders are used. Calcium dobesilate is formulated in vehicle and administered orally at doses of 10-100 mg/kg, typically once daily for 2-4 weeks. Retinal pathology is assessed by fundus examination, histopathology, and measurement of vascular permeability. Inflammatory markers and oxidative stress markers are measured in retinal tissues and blood. Blood viscosity and platelet aggregation are assessed. For pharmacokinetic studies, blood samples are collected at various time points for compound quantification by LC-MS.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Calcium dobesilate indicate that it is orally active with moderate bioavailability. The compound is absorbed from the gastrointestinal tract and distributed to various tissues. It is metabolized in the liver and excreted in the urine. The compound's pharmacokinetic properties support its use as an oral therapeutic agent for chronic venous disease and diabetic retinopathy.
|
| Toxicity/Toxicokinetics |
Toxicological data for Calcium dobesilate are well-established from clinical use. The compound is generally well-tolerated, with gastrointestinal side effects being the most common. No significant organ toxicity has been reported. The compound has anti-inflammatory, antioxidant, and vasoprotective properties. It is contraindicated in patients with hypersensitivity to the compound. Monitoring of renal function is recommended in patients with renal impairment.
|
| Additional Infomation |
A drug used to reduce bleeding in diabetic retinopathy.
Calcium dobesilate (CAS 20123-80-2) is a vasoprotective agent used for chronic venous disease, diabetic retinopathy, and hemorrhoidal attacks. It has a molecular formula of 2C₆H₅O₅S·Ca and a molecular weight of 418.41. The compound has anti-inflammatory, antioxidant, and vasoprotective properties. It reduces blood hyper viscosity, restores normal flow, and prevents platelet hyper-aggregation. It can clear hydroxyl free radicals with an IC50 of 1.1 pM. Calcium dobesilate is used as a therapeutic agent in many countries. |
| Molecular Formula |
C12H10CAO10S2
|
|---|---|
| Molecular Weight |
418.41
|
| Exact Mass |
417.934
|
| CAS # |
20123-80-2
|
| Related CAS # |
Dobesilate-d6 calcium
|
| PubChem CID |
29963
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.165
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
228
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=S(C1=CC(O)=CC=C1O)([O-])=O.O=S(C2=CC(O)=CC=C2O)([O-])=O.[Ca+2]
|
| InChi Key |
QGNBTYAQAPLTMX-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C6H6O5S.Ca/c2*7-4-1-2-5(8)6(3-4)12(9,10)11;/h2*1-3,7-8H,(H,9,10,11);/q;;+2/p-2
|
| Chemical Name |
calcium;2,5-dihydroxybenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~150 mg/mL (~358.50 mM)
H2O : ≥ 100 mg/mL (~239.00 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3900 mL | 11.9500 mL | 23.9000 mL | |
| 5 mM | 0.4780 mL | 2.3900 mL | 4.7800 mL | |
| 10 mM | 0.2390 mL | 1.1950 mL | 2.3900 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
